Skip to content

Atomoxetine Versus Placebo for Symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents With Autism Spectrum Disorder

A Randomized, Double-blind Comparison of Atomoxetine Hydrochloride and Placebo for Symptoms of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents With Autism Spectrum Disorder

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00380692
Enrollment
97
Registered
2006-09-26
Start date
2006-10-31
Completion date
2008-10-31
Last updated
2010-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention Deficit Disorder With Hyperactivity, Autistic Disorder

Brief summary

The purpose of this study is to determine whether atomoxetine is effective in reducing ADHD (Attention Deficit/Hyperactivity Disorder) symptoms in children and adolescents with ASD (Autism Spectrum Disorder).

Interventions

DRUGAtomoxetine
DRUGPlacebo

Sponsors

Eli Lilly and Company
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
6 Years to 17 Years
Healthy volunteers
No

Inclusion criteria

(most important): * ASD (autistic disorder or Asperger's disorder or Pervasive Developmental Disorder - Not Otherwise Specified \[PDD NOS\]) * Criteria A through D for Attention-Deficit/Hyperactivity Disorder (ADHD) * At least 1.5 standard deviations above the age norm for their diagnostic subtype using published norms for the ADHD Rating Scale-IV-Parent Version * Intelligence quotient (IQ) score \> 60

Exclusion criteria

(most important): * weight under 20 kg * Patients who meet Diagnostic and Statistical Manual of Mental Disorders Fourth Edition, Text Revision (DSM-IV-TR) criteria for ASD other than Autistic Disorder, PDD-NOS or Asperger's Disorder;history of Bipolar I or II disorder, schizophrenia, another psychotic disorder, substance abuse;Have a significant medical condition such as heart disease, hypertension, liver or renal failure, pulmonary disease, or seizure disorder identified by history, physical examination, or laboratory tests; Patients who have taken (or are currently taking) anticonvulsants for seizure control. * patients at serious suicidal risk. * Contraindication to the use of atomoxetine * Patients who in the investigator's judgment are likely to need psychotropic medications apart from the drug. Patients who at any time during Study Period II are likely to begin a structured psychotherapy, likely to require hospitalization (i.e. in-patient treatment) or likely to be dismissed from in-patient treatment. Psychotherapy (including hospitalization) initiated at least 2 months prior to study participation is acceptable; however, after study participation has begun, only during Study Period III supportive or educational therapy is permitted.

Design outcomes

Primary

MeasureTime frameDescription
ADHD Rating Scale-IV-Parent Version: Investigator Scored - Total ScoreBaseline and 8 weeksMeasures the 18 symptoms contained in the Diagnostic and Statistical Manual of Mental Disorders, Version IV (DSM-IV) diagnosis of Attention-Deficit/Hyperactivity Disorder. Individual item scores range from 0 (none/never or rarely) to 3 (severe/very often). Total scores range from 0 to 54.

Secondary

MeasureTime frameDescription
Conners' Teacher Rating Scale - Revised: Short Form (CTRS-R:S)Baseline, 8 weeks, 28 weeksA 28-item rating scale (0 \[not at all/never\] to 3 \[very much true/very often\]) completed by the teacher to assess problem behaviors related to ADHD. Subscale total scores range from 0 to 15 for Oppositional and Cognitive Problems, 0 to 21 for Hyperactivity, and 0 to 36 for ADHD Index.
ADHD Rating Scale-IV-Parent Version: Investigator Scored Total Score28 weeksMeasures the 18 symptoms contained in the DSM-IV diagnosis of Attention-Deficit/Hyperactivity Disorder. Individual item scores range from 0 (none/never or rarely) to 3 (severe/very often). Total scores range from 0 to 54.
Sleep Measure ScaleBaseline, 8 weeks, 28 weeks10-item parent-based scale assessing sleep problems (6 point Likert scale). Scores: Difficulty falling asleep (1-6); Quality of sleep (3-18); Functional outcome (6-36). Lower scores indicate higher problems with item. Open-ended items: Time to fall asleep (1 \[0-15 minutes\] to 5 \[\>1 hour\]); Total hours (numbers associated with hours of sleep).
Aberrant Behavior Checklist (ABC)Baseline, 8 weeks, 28 weeksThe ABC is a 58-item informant-based scale comprised of five subscales (Irritability \[15 items\], Lethargy \[16\], Stereotypic Behaviors \[7\], Hyperactivity \[16\], Inappropriate Speech \[4\]). Individual item scores range from 0 (no problem) to 3 (severe problem). Subscale scores are total of individual item scores in subscale: Irritability (0-45); Lethargy (0-48); Stereotypic (0-21); Hyperactivity (0-48); Inappropriate Speech (0-12).
Children's Social Behavior Questionnaire (CSBQ) Total ScoreBaseline, 8 weeks, 28 weeksCSBQ is filled out by parents and consists of 49 items. Items are rated in an ordinal rather than a discrete fashion in order to establish the extent to which problems are present. The CSBQ consists of six subscales. Individual item scores range from 0=does not apply to 2=applies clearly. Total score ranges from 0 to 98.
General Health Questionnaire (GHQ) Total ScoreBaseline, 8 weeks, 28 weeksParental distress is measured with the GHQ. The raw total score (based on 0-0-1-1 scoring system) can be used as an overall index of psychological distress, ranging from 0 to 12 with higher scores indicating more distress.
Nijmeegse Ouderlijke Stress Index (NOSI) Total ScoreBaseline, 8 weeks, 28 weeksThe NOSI contains 123 items to be completed by the primary caregiver. Individual item scores range from 1 (completely agree) to 6 (completely disagree). Total scores range from 123 to 738.
Amsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Error RatesBaseline, 8 WeeksFocused attention assessed distractibility. Child needs to identify a specific target (eg, Cherry); non-target is any other fruit. Child presses yes when target occurs in relevant position (eg, one of vertical positions on diamond). Child presses no when target is absent, or when target appears on horizontal position (irrelevant target). Error rates are percentage of missing relevant targets and percentage of false alarms in response to (irr)relevant (non)targets based on number of errors/total number of trials X 100.
Amsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Reaction Times for Hits and Correct RejectionsBaseline, 8 WeeksTask is the same as described in Outcome Measure #10. Reaction times (RT) for hits are mean RTs of correct responses to relevant targets. RTs for correct rejections are mean RTs for correct rejections are mean RTs for correct no responses to irrelevant targets and relevant nontargets.
Clinical Global Impressions-ADHD-Improvement (CGI-ADHD - I)8 weeks, 28 weeksMeasures total improvement (or worsening) of a patient's ADHD symptoms from the beginning of treatment (1=very much improved, 7=very much worsened).
Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Error RatesBaseline, 8 WeeksThe memory search task aims at measuring serial search processes to be carried out in working memory. There are 2 blocks (loads) with 40 trials each. Load 1 has 1 target to identify (e.g., an animal). A yes is required whenever the target is part of the displayed set of four stimuli (all animals). Load 2 has 2 targets. Whenever 1 of the targets appears in the successively displayed sets of four animals, a yes is required. Targets are present in 50% of trials. Error rates are the percentages of errors made in each task condition, based on the number of errors/total number of trials X 100.
Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Reaction Times for Hits and Correct RejectionsBaseline, 8 WeeksMemory search task aims at measuring serial search processes to be carried out in working memory. There are 2 blocks (loads) with 40 trials each. Load 1 has 1 target to remember (one animal). A yes is required whenever the target is part of displayed set of 4 animals. Load 2 has 2 animals. A yes is required whenever one of the animals appears in successively displayed sets of 4 animals. Targets are present in 50% of the trials. Reaction time (RT) for hits is mean RT of correct yes responses to targets. RT correct rejections are mean RTs of correct no responses when target was missing.
Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Standard Deviation (SD) of Reaction Times for Hits and Correct RejectionsBaseline, 8 weeksTask is the same as described in Outcome Measure #14. Standard deviations of reaction times (RT) assess intraindividual variability in RT referring to the two conditions creating hits and correct rejections as mentioned in Outcome Measure #14.
Amsterdam Neuropsychological Tasks (ANT): Pursuit Motor Control Task - AccuracyBaseline, 8 weeksA complex visuo-motor flexibility task that aims at measuring eye-hand co-ordination and fine motor control. By moving mouse cursor, the child is required to follow as closely as possible a target that randomly moves across the PC-screen. Accuracy is the mean distance between the mouse cursor and the moving target.
Amsterdam Neuropsychological Tasks (ANT): Pursuit Motor Control Task - Stability of MovementBaseline, 8 weeksA complex visuo-motor flexibility task that measures eye-hand co-ordination and fine motor control. By moving mouse cursor, the child is required to follow as closely as possible a target that randomly moves across the PC-screen. Stability is within subject variability of mean distance between cursor and target.
Amsterdam Neuropsychological Tasks (ANT): Go/No-Go Response Inhibition Task - Error RatesBaseline, 8 weeksMeasures inhibition of pre-potent responses. 24 Go signals (open squares) are presented, randomly mixed with 24 No-Go signals (closed squares). Subjects are required to press a key if a Go signal (target) appears on the screen but to withhold a response if they see a No-Go signal. Error rate is the percentage of key presses to No-Go signals/total number of trials X 100.
Amsterdam Neuropsychological Tasks (ANT): Flanker Interference Task - Error RatesBaseline, 8 weeksMeasures ability to neglect stimuli interfering with predefined stimulus-response coupling. Child presented with displays of 9 colored squares. Child responds to color of central square by pressing left mouse key when blue, and right mouse key when yellow. Part 1 (40 trials), surrounding squares may be same color (compatible) or different (neutral). Part 2 (80 trials), in 50% of trials, surrounding squares have color corresponding to predefined key press for other hand (incompatible). Error rates are percentages of errors in response to compatible and incompatible signals, respectively.
Amsterdam Neuropsychological Tasks (ANT): Flanker Interference Task - Reaction TimesBaseline, 8 weeksTask is the same as described in Outcome Measure #19. Mean reaction times (RTs) are computed for correct responses to compatible and incompatible flankers, respectively.
Cytochrome P450 2D6 GenotypebaselineGenotype characterization was used to determine participants' metabolic status.
Amsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Standard Deviation of Reaction Times for Hits and Correct RejectionsBaseline, 8 WeeksTask is the same as described in Outcome Measure #10. Standard deviations of reaction times (RT) assess intraindividual variability in RT and refer to the same conditions as those for mean reaction times described in Outcome Measure #11.

Countries

Netherlands

Participant flow

Pre-assignment details

Study Period I was a screening and wash-out period. Study Period II (visits 2-6) was an 8-week double-blind period. Patients were randomized at Visit 2. Study Period III (visits 6-11) was a 20-week open-label extension period. Treatment groups in Study Period III refer to treatment group assignment during Double-Blind Period.

Participants by arm

ArmCount
Atomoxetine
atomoxetine: 0.5 mg/kg/day daily (QD), by mouth (PO) for 1 week, atomoxetine 0.8mg/kg/day QD, PO for 1 week, 1.2mg/kg/day QD, PO for 6 weeks then atomoxetine 0.5-1.2 mg/kg/day QD, PO for up to 20 weeks.
48
Placebo
placebo: daily (QD), by mouth (PO) for 8 weeks. Then patients can take atomoxetine 0.5-1.2 mg/kg/day QD, PO up to 20 weeks.
49
Total97

Withdrawals & dropouts

PeriodReasonFG000FG001
Study Period II - Double BlindAdverse Event10
Study Period II - Double BlindLack of Efficacy10
Study Period II - Double BlindParent/Caregiver Decision10
Study Period II - Double BlindPhysician Decision01
Study Period II - Double BlindProtocol Violation22
Study Period II - Double BlindWithdrawal by Subject00
Study Period III - Open LabelAdverse Event53
Study Period III - Open LabelLack of Efficacy04
Study Period III - Open LabelParent/Caregiver Decision11
Study Period III - Open LabelPhysician Decision03
Study Period III - Open LabelProtocol Violation00
Study Period III - Open LabelWithdrawal by Subject01

Baseline characteristics

CharacteristicAtomoxetineTotalPlacebo
Age Continuous9.9 years
STANDARD_DEVIATION 2.72
9.9 years
STANDARD_DEVIATION 2.8
10.0 years
STANDARD_DEVIATION 2.9
Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version- Total Score40.7 units on a scale
STANDARD_DEVIATION 7.47
39.6 units on a scale
STANDARD_DEVIATION 8
38.6 units on a scale
STANDARD_DEVIATION 8.43
Autism Diagnostic Interview-Revised (ADI-R)37.4 units on a scale
STANDARD_DEVIATION 12.45
37.3 units on a scale
STANDARD_DEVIATION 11.09
37.2 units on a scale
STANDARD_DEVIATION 9.68
Body Mass Index18.5 kilogram/meter squared
STANDARD_DEVIATION 3.4
18.3 kilogram/meter squared
STANDARD_DEVIATION 3.37
18.1 kilogram/meter squared
STANDARD_DEVIATION 3.36
Clinical Global Impression-Attention Deficit Hyperactivity Disorder-Severity Scale5.0 units on a scale
STANDARD_DEVIATION 0.74
5.1 units on a scale
STANDARD_DEVIATION 0.83
5.1 units on a scale
STANDARD_DEVIATION 0.9
Height146.0 centimeters
STANDARD_DEVIATION 16.57
147.0 centimeters
STANDARD_DEVIATION 17.84
148.0 centimeters
STANDARD_DEVIATION 19.11
Race/Ethnicity
African
0 participants1 participants1 participants
Race/Ethnicity
Caucasian
48 participants95 participants47 participants
Race/Ethnicity
Hispanic
0 participants1 participants1 participants
Region of Enrollment
Netherlands
48 participants97 participants49 participants
Score for Performance IQ89.9 units on a scale
STANDARD_DEVIATION 16.59
92.4 units on a scale
STANDARD_DEVIATION 17.14
94.9 units on a scale
STANDARD_DEVIATION 17.46
Score for the Overall Scale Intelligence91.0 units on a scale
STANDARD_DEVIATION 16.41
92.9 units on a scale
STANDARD_DEVIATION 17.08
94.6 units on a scale
STANDARD_DEVIATION 17.71
Score for Verbal IQ93.2 units on a scale
STANDARD_DEVIATION 18.49
93.8 units on a scale
STANDARD_DEVIATION 18.29
94.4 units on a scale
STANDARD_DEVIATION 18.26
Sex: Female, Male
Female
6 Participants14 Participants8 Participants
Sex: Female, Male
Male
42 Participants83 Participants41 Participants
Weight41.0 kilograms
STANDARD_DEVIATION 14.92
41.2 kilograms
STANDARD_DEVIATION 15.46
41.5 kilograms
STANDARD_DEVIATION 16.12

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
39 / 4832 / 49
serious
Total, serious adverse events
0 / 480 / 49

Outcome results

Primary

ADHD Rating Scale-IV-Parent Version: Investigator Scored - Total Score

Measures the 18 symptoms contained in the Diagnostic and Statistical Manual of Mental Disorders, Version IV (DSM-IV) diagnosis of Attention-Deficit/Hyperactivity Disorder. Individual item scores range from 0 (none/never or rarely) to 3 (severe/very often). Total scores range from 0 to 54.

Time frame: Baseline and 8 weeks

Population: Number of randomized participants with a value at baseline and 8 week endpoint. Last Observation Carried Forward analysis.

ArmMeasureGroupValue (MEAN)Dispersion
AtomoxetineADHD Rating Scale-IV-Parent Version: Investigator Scored - Total ScoreBaseline Total Score (n=48, n=49)40.7 units on a scaleStandard Deviation 7.47
AtomoxetineADHD Rating Scale-IV-Parent Version: Investigator Scored - Total Score8 Week Endpoint Total Score (n=43, n=47)32.3 units on a scaleStandard Deviation 10.97
PlaceboADHD Rating Scale-IV-Parent Version: Investigator Scored - Total ScoreBaseline Total Score (n=48, n=49)38.6 units on a scaleStandard Deviation 8.43
PlaceboADHD Rating Scale-IV-Parent Version: Investigator Scored - Total Score8 Week Endpoint Total Score (n=43, n=47)37.3 units on a scaleStandard Deviation 9.57
p-value: <0.00195% CI: [-10, -3.4]Mixed Models Analysis
Secondary

Aberrant Behavior Checklist (ABC)

The ABC is a 58-item informant-based scale comprised of five subscales (Irritability \[15 items\], Lethargy \[16\], Stereotypic Behaviors \[7\], Hyperactivity \[16\], Inappropriate Speech \[4\]). Individual item scores range from 0 (no problem) to 3 (severe problem). Subscale scores are total of individual item scores in subscale: Irritability (0-45); Lethargy (0-48); Stereotypic (0-21); Hyperactivity (0-48); Inappropriate Speech (0-12).

Time frame: Baseline, 8 weeks, 28 weeks

Population: Randomized participants with values at timepoint.

ArmMeasureGroupValue (MEAN)Dispersion
AtomoxetineAberrant Behavior Checklist (ABC)Lethargy: 8 Week (n=43, n=46)11.1 units on a scaleStandard Deviation 9.34
AtomoxetineAberrant Behavior Checklist (ABC)Stereotypic: 28 Week (n=38, n=36)3.3 units on a scaleStandard Deviation 4.03
AtomoxetineAberrant Behavior Checklist (ABC)Irritiability: 8 Week (n=43, n=46)14.5 units on a scaleStandard Deviation 9.36
AtomoxetineAberrant Behavior Checklist (ABC)Hyperactivity: Baseline (n=47, n=49)28.2 units on a scaleStandard Deviation 9.4
AtomoxetineAberrant Behavior Checklist (ABC)Lethargy: 28 Week (n=38 , n=36)7.5 units on a scaleStandard Deviation 7.24
AtomoxetineAberrant Behavior Checklist (ABC)Hyperactivity: 8 Week (n=43, n=45)22.5 units on a scaleStandard Deviation 11.05
AtomoxetineAberrant Behavior Checklist (ABC)Lethargy: Baseline (n=47, n=49)12.7 units on a scaleStandard Deviation 8.33
AtomoxetineAberrant Behavior Checklist (ABC)Hyperactivity: 28 Week (n=38, n=36)16.4 units on a scaleStandard Deviation 12.17
AtomoxetineAberrant Behavior Checklist (ABC)Stereotypic: Baseline (n=47, n=49)6.6 units on a scaleStandard Deviation 5.07
AtomoxetineAberrant Behavior Checklist (ABC)Inappropriate Speech: Baseline (n=47, n=49)4.8 units on a scaleStandard Deviation 3.21
AtomoxetineAberrant Behavior Checklist (ABC)Irritiability: 28 Week (n=38, n=36)11.5 units on a scaleStandard Deviation 10.12
AtomoxetineAberrant Behavior Checklist (ABC)Inappropriate Speech: 8 Week (n=43, n=46)3.8 units on a scaleStandard Deviation 2.92
AtomoxetineAberrant Behavior Checklist (ABC)Stereotypic: 8 Week (n=43, n=46)3.6 units on a scaleStandard Deviation 4.01
AtomoxetineAberrant Behavior Checklist (ABC)Inappropriate Speech: 28 Week (n=38, n=36)3.1 units on a scaleStandard Deviation 3.22
AtomoxetineAberrant Behavior Checklist (ABC)Irritiability: Baseline (n=47, n=49)17.4 units on a scaleStandard Deviation 9.15
PlaceboAberrant Behavior Checklist (ABC)Inappropriate Speech: 28 Week (n=38, n=36)2.9 units on a scaleStandard Deviation 2.35
PlaceboAberrant Behavior Checklist (ABC)Irritiability: Baseline (n=47, n=49)16.2 units on a scaleStandard Deviation 9.49
PlaceboAberrant Behavior Checklist (ABC)Irritiability: 8 Week (n=43, n=46)15.4 units on a scaleStandard Deviation 9.8
PlaceboAberrant Behavior Checklist (ABC)Irritiability: 28 Week (n=38, n=36)10.4 units on a scaleStandard Deviation 8.05
PlaceboAberrant Behavior Checklist (ABC)Lethargy: Baseline (n=47, n=49)12.5 units on a scaleStandard Deviation 8.03
PlaceboAberrant Behavior Checklist (ABC)Lethargy: 8 Week (n=43, n=46)11.5 units on a scaleStandard Deviation 8.17
PlaceboAberrant Behavior Checklist (ABC)Lethargy: 28 Week (n=38 , n=36)8.4 units on a scaleStandard Deviation 6.64
PlaceboAberrant Behavior Checklist (ABC)Stereotypic: Baseline (n=47, n=49)4.1 units on a scaleStandard Deviation 4.47
PlaceboAberrant Behavior Checklist (ABC)Stereotypic: 8 Week (n=43, n=46)3.6 units on a scaleStandard Deviation 4.12
PlaceboAberrant Behavior Checklist (ABC)Stereotypic: 28 Week (n=38, n=36)1.7 units on a scaleStandard Deviation 2.77
PlaceboAberrant Behavior Checklist (ABC)Hyperactivity: Baseline (n=47, n=49)25.5 units on a scaleStandard Deviation 11.56
PlaceboAberrant Behavior Checklist (ABC)Hyperactivity: 8 Week (n=43, n=45)24.6 units on a scaleStandard Deviation 10.33
PlaceboAberrant Behavior Checklist (ABC)Hyperactivity: 28 Week (n=38, n=36)16.0 units on a scaleStandard Deviation 9.6
PlaceboAberrant Behavior Checklist (ABC)Inappropriate Speech: Baseline (n=47, n=49)4.6 units on a scaleStandard Deviation 3.35
PlaceboAberrant Behavior Checklist (ABC)Inappropriate Speech: 8 Week (n=43, n=46)4.5 units on a scaleStandard Deviation 3.26
p-value: 0.45295% CI: [-3.5, 1.6]ANCOVA
p-value: 0.8595% CI: [-2.4, 2]ANCOVA
p-value: 0.01495% CI: [-2.8, -0.3]ANCOVA
p-value: 0.0195% CI: [-7.8, -1.1]ANCOVA
p-value: 0.04595% CI: [-1.7, 0]ANCOVA
Secondary

ADHD Rating Scale-IV-Parent Version: Investigator Scored Total Score

Measures the 18 symptoms contained in the DSM-IV diagnosis of Attention-Deficit/Hyperactivity Disorder. Individual item scores range from 0 (none/never or rarely) to 3 (severe/very often). Total scores range from 0 to 54.

Time frame: 28 weeks

Population: Randomized participants with a value at timepoint.

ArmMeasureValue (MEAN)Dispersion
AtomoxetineADHD Rating Scale-IV-Parent Version: Investigator Scored Total Score23.6 units on a scaleStandard Deviation 11.81
PlaceboADHD Rating Scale-IV-Parent Version: Investigator Scored Total Score25.9 units on a scaleStandard Deviation 10.58
Secondary

Amsterdam Neuropsychological Tasks (ANT): Flanker Interference Task - Error Rates

Measures ability to neglect stimuli interfering with predefined stimulus-response coupling. Child presented with displays of 9 colored squares. Child responds to color of central square by pressing left mouse key when blue, and right mouse key when yellow. Part 1 (40 trials), surrounding squares may be same color (compatible) or different (neutral). Part 2 (80 trials), in 50% of trials, surrounding squares have color corresponding to predefined key press for other hand (incompatible). Error rates are percentages of errors in response to compatible and incompatible signals, respectively.

Time frame: Baseline, 8 weeks

Population: Number of participants with baseline and one non-missing postbaseline value at visit.

ArmMeasureGroupValue (MEAN)Dispersion
AtomoxetineAmsterdam Neuropsychological Tasks (ANT): Flanker Interference Task - Error RatesCompatible Signals Baseline (n=32, n=35)7.7 error rate (percentages)Standard Deviation 9.8
AtomoxetineAmsterdam Neuropsychological Tasks (ANT): Flanker Interference Task - Error RatesCompatible Signals 8 Week (n=33, n=35)-2.1 error rate (percentages)Standard Deviation 8.92
AtomoxetineAmsterdam Neuropsychological Tasks (ANT): Flanker Interference Task - Error RatesIncompatible Signals Baseline (n=32, n=35)8.4 error rate (percentages)Standard Deviation 10.33
AtomoxetineAmsterdam Neuropsychological Tasks (ANT): Flanker Interference Task - Error RatesIncompatible Signals 8 Week (n=32, n=35)-0.4 error rate (percentages)Standard Deviation 11.11
PlaceboAmsterdam Neuropsychological Tasks (ANT): Flanker Interference Task - Error RatesIncompatible Signals 8 Week (n=32, n=35)0.1 error rate (percentages)Standard Deviation 8.19
PlaceboAmsterdam Neuropsychological Tasks (ANT): Flanker Interference Task - Error RatesCompatible Signals Baseline (n=32, n=35)8.5 error rate (percentages)Standard Deviation 10.06
PlaceboAmsterdam Neuropsychological Tasks (ANT): Flanker Interference Task - Error RatesIncompatible Signals Baseline (n=32, n=35)9.1 error rate (percentages)Standard Deviation 6.62
PlaceboAmsterdam Neuropsychological Tasks (ANT): Flanker Interference Task - Error RatesCompatible Signals 8 Week (n=33, n=35)-1.8 error rate (percentages)Standard Deviation 11.43
p-value: 0.22195% CI: [-9.6, 2.3]Mixed Models Analysis
p-value: 0.30795% CI: [-2.1, 6.3]Mixed Models Analysis
Secondary

Amsterdam Neuropsychological Tasks (ANT): Flanker Interference Task - Reaction Times

Task is the same as described in Outcome Measure #19. Mean reaction times (RTs) are computed for correct responses to compatible and incompatible flankers, respectively.

Time frame: Baseline, 8 weeks

Population: Number of participants with baseline and non-missing postbaseline value at visit.

ArmMeasureGroupValue (MEAN)Dispersion
AtomoxetineAmsterdam Neuropsychological Tasks (ANT): Flanker Interference Task - Reaction TimesCompatible Flankers Part 2 Baseline (n=31,n=34)863.1 millisecondsStandard Deviation 234.7
AtomoxetineAmsterdam Neuropsychological Tasks (ANT): Flanker Interference Task - Reaction TimesCompatible Flankers Part 2 8 Week (n=33,n=35)901.1 millisecondsStandard Deviation 350.27
AtomoxetineAmsterdam Neuropsychological Tasks (ANT): Flanker Interference Task - Reaction TimesIncompatible Flankers Part 2 Baseline (n=31,n=35)959.4 millisecondsStandard Deviation 295.32
AtomoxetineAmsterdam Neuropsychological Tasks (ANT): Flanker Interference Task - Reaction TimesIncompatible Flankers Part 2 8 Week (n=33,n=35)931.9 millisecondsStandard Deviation 347.99
PlaceboAmsterdam Neuropsychological Tasks (ANT): Flanker Interference Task - Reaction TimesIncompatible Flankers Part 2 8 Week (n=33,n=35)946.2 millisecondsStandard Deviation 419.63
PlaceboAmsterdam Neuropsychological Tasks (ANT): Flanker Interference Task - Reaction TimesCompatible Flankers Part 2 Baseline (n=31,n=34)925.4 millisecondsStandard Deviation 384.55
PlaceboAmsterdam Neuropsychological Tasks (ANT): Flanker Interference Task - Reaction TimesIncompatible Flankers Part 2 Baseline (n=31,n=35)976.5 millisecondsStandard Deviation 412.76
PlaceboAmsterdam Neuropsychological Tasks (ANT): Flanker Interference Task - Reaction TimesCompatible Flankers Part 2 8 Week (n=33,n=35)897.7 millisecondsStandard Deviation 376.63
p-value: 0.75295% CI: [-163.1, 119.1]Mixed Models Analysis
p-value: 0.56495% CI: [-47, 84.3]Mixed Models Analysis
Secondary

Amsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Error Rates

Focused attention assessed distractibility. Child needs to identify a specific target (eg, Cherry); non-target is any other fruit. Child presses yes when target occurs in relevant position (eg, one of vertical positions on diamond). Child presses no when target is absent, or when target appears on horizontal position (irrelevant target). Error rates are percentage of missing relevant targets and percentage of false alarms in response to (irr)relevant (non)targets based on number of errors/total number of trials X 100.

Time frame: Baseline, 8 Weeks

Population: Number of participants with baseline and a non-missing postbaseline value at visit.

ArmMeasureGroupValue (MEAN)Dispersion
AtomoxetineAmsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Error RatesIrrelevant Targets Baseline (n=35, n=44)12.3 error rate (percentage)Standard Deviation 13.95
AtomoxetineAmsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Error RatesIrrelevant Targets 8 Week (n=35, n=44)10.0 error rate (percentage)Standard Deviation 16.09
AtomoxetineAmsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Error RatesRelevant Nontargets Baseline (n=35, n=44)5.7 error rate (percentage)Standard Deviation 8.15
AtomoxetineAmsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Error RatesRelevant Nontargets 8 Week (n=35, n=44)5.1 error rate (percentage)Standard Deviation 9.48
AtomoxetineAmsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Error RatesRelevant Targets Baseline (n=35, n=44)4.8 error rate (percentage)Standard Deviation 5.49
AtomoxetineAmsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Error RatesRelevant Targets 8 Week (n=35, n=44)7.3 error rate (percentage)Standard Deviation 9.42
PlaceboAmsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Error RatesRelevant Targets Baseline (n=35, n=44)6.9 error rate (percentage)Standard Deviation 9.04
PlaceboAmsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Error RatesIrrelevant Targets Baseline (n=35, n=44)11.8 error rate (percentage)Standard Deviation 16.06
PlaceboAmsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Error RatesRelevant Nontargets 8 Week (n=35, n=44)3.3 error rate (percentage)Standard Deviation 7.04
PlaceboAmsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Error RatesIrrelevant Targets 8 Week (n=35, n=44)13.3 error rate (percentage)Standard Deviation 14.36
PlaceboAmsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Error RatesRelevant Targets 8 Week (n=35, n=44)7.2 error rate (percentage)Standard Deviation 14.47
PlaceboAmsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Error RatesRelevant Nontargets Baseline (n=35, n=44)2.9 error rate (percentage)Standard Deviation 5.97
p-value: 0.94895% CI: [-5.5, 5.2]Mixed Models Analysis
p-value: 0.39995% CI: [-9.7, 3.9]Mixed Models Analysis
p-value: 0.5795% CI: [-4.3, 7.8]Mixed Models Analysis
Secondary

Amsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Reaction Times for Hits and Correct Rejections

Task is the same as described in Outcome Measure #10. Reaction times (RT) for hits are mean RTs of correct responses to relevant targets. RTs for correct rejections are mean RTs for correct rejections are mean RTs for correct no responses to irrelevant targets and relevant nontargets.

Time frame: Baseline, 8 Weeks

Population: Number of participants with baseline and a non-missing postbaseline value at visit.

ArmMeasureGroupValue (MEAN)Dispersion
AtomoxetineAmsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Reaction Times for Hits and Correct RejectionsIrrelevant Target Baseline (n=34, n=42)1260.1 millisecondsStandard Deviation 413.09
AtomoxetineAmsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Reaction Times for Hits and Correct RejectionsIrrelevant Target 8 Week (n=32, n=43)1167.8 millisecondsStandard Deviation 493.57
AtomoxetineAmsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Reaction Times for Hits and Correct RejectionsRelevant Nontarget Baseline (n=34, n=43)1208.4 millisecondsStandard Deviation 509.62
AtomoxetineAmsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Reaction Times for Hits and Correct RejectionsRelevant Nontarget 8 Week (n=33, n=43)1165.4 millisecondsStandard Deviation 570.35
AtomoxetineAmsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Reaction Times for Hits and Correct RejectionsMean Reaction Time Hits Baseline (n=34, n=42)1045.6 millisecondsStandard Deviation 411.14
AtomoxetineAmsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Reaction Times for Hits and Correct RejectionsMean Reaction Time Hits 8 Week (n=33, n=43)1013.0 millisecondsStandard Deviation 505.52
PlaceboAmsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Reaction Times for Hits and Correct RejectionsMean Reaction Time Hits Baseline (n=34, n=42)1084.4 millisecondsStandard Deviation 518.5
PlaceboAmsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Reaction Times for Hits and Correct RejectionsIrrelevant Target Baseline (n=34, n=42)1217.3 millisecondsStandard Deviation 533.92
PlaceboAmsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Reaction Times for Hits and Correct RejectionsRelevant Nontarget 8 Week (n=33, n=43)1168.9 millisecondsStandard Deviation 569.16
PlaceboAmsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Reaction Times for Hits and Correct RejectionsIrrelevant Target 8 Week (n=32, n=43)1206.0 millisecondsStandard Deviation 547.64
PlaceboAmsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Reaction Times for Hits and Correct RejectionsMean Reaction Time Hits 8 Week (n=33, n=43)1017.7 millisecondsStandard Deviation 475.82
PlaceboAmsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Reaction Times for Hits and Correct RejectionsRelevant Nontarget Baseline (n=34, n=43)1220.9 millisecondsStandard Deviation 550.25
p-value: 0.35295% CI: [-193.5, 69.8]Mixed Models Analysis
p-value: 0.55395% CI: [-160.3, 86.2]Mixed Models Analysis
p-value: 0.90495% CI: [-107.1, 121.1]Mixed Models Analysis
Secondary

Amsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Standard Deviation of Reaction Times for Hits and Correct Rejections

Task is the same as described in Outcome Measure #10. Standard deviations of reaction times (RT) assess intraindividual variability in RT and refer to the same conditions as those for mean reaction times described in Outcome Measure #11.

Time frame: Baseline, 8 Weeks

Population: Number of participants with baseline and a non-missing postbaseline value at visit.

ArmMeasureGroupValue (MEAN)Dispersion
AtomoxetineAmsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Standard Deviation of Reaction Times for Hits and Correct RejectionsIrrelevant Target Baseline (n=33, n=39)421.0 millisecondsStandard Deviation 263.84
AtomoxetineAmsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Standard Deviation of Reaction Times for Hits and Correct RejectionsIrrelevant Target 8 Week (n=29, n=41)341.0 millisecondsStandard Deviation 259.84
AtomoxetineAmsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Standard Deviation of Reaction Times for Hits and Correct RejectionsRelevant Nontarget Baseline (n=33, n=40)442.2 millisecondsStandard Deviation 374.99
AtomoxetineAmsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Standard Deviation of Reaction Times for Hits and Correct RejectionsRelevant Nontarget 8 Week (n=30, n=41)442.6 millisecondsStandard Deviation 413.74
AtomoxetineAmsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Standard Deviation of Reaction Times for Hits and Correct RejectionsStandard Deviation Hits Baseline (n=33, n=39)434.3 millisecondsStandard Deviation 302.61
AtomoxetineAmsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Standard Deviation of Reaction Times for Hits and Correct RejectionsStandard Deviation Hits 8 Week (n=30, n=41)381.5 millisecondsStandard Deviation 286.96
PlaceboAmsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Standard Deviation of Reaction Times for Hits and Correct RejectionsStandard Deviation Hits Baseline (n=33, n=39)497.9 millisecondsStandard Deviation 365.48
PlaceboAmsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Standard Deviation of Reaction Times for Hits and Correct RejectionsIrrelevant Target Baseline (n=33, n=39)429.4 millisecondsStandard Deviation 382.61
PlaceboAmsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Standard Deviation of Reaction Times for Hits and Correct RejectionsRelevant Nontarget 8 Week (n=30, n=41)455.6 millisecondsStandard Deviation 376.87
PlaceboAmsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Standard Deviation of Reaction Times for Hits and Correct RejectionsIrrelevant Target 8 Week (n=29, n=41)431.7 millisecondsStandard Deviation 363.62
PlaceboAmsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Standard Deviation of Reaction Times for Hits and Correct RejectionsStandard Deviation Hits 8 Week (n=30, n=41)393.9 millisecondsStandard Deviation 299.08
PlaceboAmsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Standard Deviation of Reaction Times for Hits and Correct RejectionsRelevant Nontarget Baseline (n=33, n=40)565.6 millisecondsStandard Deviation 455.54
p-value: 0.74895% CI: [-152.8, 110.3]Mixed Models Analysis
p-value: 0.29995% CI: [-234.3, 72.5]Mixed Models Analysis
p-value: 0.8495% CI: [-119.3, 146.5]Mixed Models Analysis
Secondary

Amsterdam Neuropsychological Tasks (ANT): Go/No-Go Response Inhibition Task - Error Rates

Measures inhibition of pre-potent responses. 24 Go signals (open squares) are presented, randomly mixed with 24 No-Go signals (closed squares). Subjects are required to press a key if a Go signal (target) appears on the screen but to withhold a response if they see a No-Go signal. Error rate is the percentage of key presses to No-Go signals/total number of trials X 100.

Time frame: Baseline, 8 weeks

Population: Number of participants with baseline and a non-missing postbaseline value at visit.

ArmMeasureGroupValue (MEAN)Dispersion
AtomoxetineAmsterdam Neuropsychological Tasks (ANT): Go/No-Go Response Inhibition Task - Error RatesAbsent Target Baseline8.0 error rate (percentage)Standard Deviation 16.3
AtomoxetineAmsterdam Neuropsychological Tasks (ANT): Go/No-Go Response Inhibition Task - Error RatesAbsent Target 8 Week4.5 error rate (percentage)Standard Deviation 4.75
AtomoxetineAmsterdam Neuropsychological Tasks (ANT): Go/No-Go Response Inhibition Task - Error RatesPresent Target Baseline2.0 error rate (percentage)Standard Deviation 5.25
AtomoxetineAmsterdam Neuropsychological Tasks (ANT): Go/No-Go Response Inhibition Task - Error RatesPresent Target 8 Week3.7 error rate (percentage)Standard Deviation 10.01
PlaceboAmsterdam Neuropsychological Tasks (ANT): Go/No-Go Response Inhibition Task - Error RatesPresent Target 8 Week1.9 error rate (percentage)Standard Deviation 5.15
PlaceboAmsterdam Neuropsychological Tasks (ANT): Go/No-Go Response Inhibition Task - Error RatesAbsent Target Baseline6.8 error rate (percentage)Standard Deviation 8.49
PlaceboAmsterdam Neuropsychological Tasks (ANT): Go/No-Go Response Inhibition Task - Error RatesPresent Target Baseline2.9 error rate (percentage)Standard Deviation 6.14
PlaceboAmsterdam Neuropsychological Tasks (ANT): Go/No-Go Response Inhibition Task - Error RatesAbsent Target 8 Week9.0 error rate (percentage)Standard Deviation 15.07
p-value: 0.4395% CI: [-2.4, 5.7]Mixed Models Analysis
p-value: 0.00595% CI: [-11.8, -2.2]Mixed Models Analysis
Secondary

Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Error Rates

The memory search task aims at measuring serial search processes to be carried out in working memory. There are 2 blocks (loads) with 40 trials each. Load 1 has 1 target to identify (e.g., an animal). A yes is required whenever the target is part of the displayed set of four stimuli (all animals). Load 2 has 2 targets. Whenever 1 of the targets appears in the successively displayed sets of four animals, a yes is required. Targets are present in 50% of trials. Error rates are the percentages of errors made in each task condition, based on the number of errors/total number of trials X 100.

Time frame: Baseline, 8 Weeks

Population: Number of participants with baseline and a non-missing postbaseline value at visit.

ArmMeasureGroupValue (MEAN)Dispersion
AtomoxetineAmsterdam Neuropsychological Tasks (ANT): Memory Search Task - Error RatesAbsent Targets Load 2 Baseline (n=33, n=35)2.0 error rate (percentage)Standard Deviation 3.52
AtomoxetineAmsterdam Neuropsychological Tasks (ANT): Memory Search Task - Error RatesAbsent Targets Load 2 8 Week (n=34, n=35)4.0 error rate (percentage)Standard Deviation 6.83
AtomoxetineAmsterdam Neuropsychological Tasks (ANT): Memory Search Task - Error RatesAbsent Targets Load 1 Baseline (n=34, n=35)5.9 error rate (percentage)Standard Deviation 14.06
AtomoxetineAmsterdam Neuropsychological Tasks (ANT): Memory Search Task - Error RatesAbsent Targets Load 1 8 Week (n=34, n=35)5.3 error rate (percentage)Standard Deviation 6.96
AtomoxetineAmsterdam Neuropsychological Tasks (ANT): Memory Search Task - Error RatesPresent Targets Load 1 Baseline (n=34, n=35)6.5 error rate (percentage)Standard Deviation 9.66
AtomoxetineAmsterdam Neuropsychological Tasks (ANT): Memory Search Task - Error RatesPresent Targets Load 1 8 Week (34, n=35)7.6 error rate (percentage)Standard Deviation 9.07
AtomoxetineAmsterdam Neuropsychological Tasks (ANT): Memory Search Task - Error RatesPresent Targets Load 2 Baseline (n=33, n=35)9.5 error rate (percentage)Standard Deviation 9.38
AtomoxetineAmsterdam Neuropsychological Tasks (ANT): Memory Search Task - Error RatesPresent Targets Load 2 8 Week (n=34, n=35)8.7 error rate (percentage)Standard Deviation 10.1
PlaceboAmsterdam Neuropsychological Tasks (ANT): Memory Search Task - Error RatesPresent Targets Load 2 8 Week (n=34, n=35)10.1 error rate (percentage)Standard Deviation 9.51
PlaceboAmsterdam Neuropsychological Tasks (ANT): Memory Search Task - Error RatesAbsent Targets Load 2 Baseline (n=33, n=35)4.4 error rate (percentage)Standard Deviation 9.61
PlaceboAmsterdam Neuropsychological Tasks (ANT): Memory Search Task - Error RatesPresent Targets Load 1 Baseline (n=34, n=35)6.6 error rate (percentage)Standard Deviation 6.84
PlaceboAmsterdam Neuropsychological Tasks (ANT): Memory Search Task - Error RatesAbsent Targets Load 2 8 Week (n=34, n=35)4.3 error rate (percentage)Standard Deviation 6.2
PlaceboAmsterdam Neuropsychological Tasks (ANT): Memory Search Task - Error RatesPresent Targets Load 2 Baseline (n=33, n=35)9.7 error rate (percentage)Standard Deviation 10.07
PlaceboAmsterdam Neuropsychological Tasks (ANT): Memory Search Task - Error RatesAbsent Targets Load 1 Baseline (n=34, n=35)5.1 error rate (percentage)Standard Deviation 5.49
PlaceboAmsterdam Neuropsychological Tasks (ANT): Memory Search Task - Error RatesPresent Targets Load 1 8 Week (34, n=35)7.9 error rate (percentage)Standard Deviation 10.93
PlaceboAmsterdam Neuropsychological Tasks (ANT): Memory Search Task - Error RatesAbsent Targets Load 1 8 Week (n=34, n=35)7.6 error rate (percentage)Standard Deviation 13.25
p-value: 0.12695% CI: [-1.2, 9.9]Mixed Models Analysis
p-value: 0.29795% CI: [-5.2, 1.6]Mixed Models Analysis
p-value: 0.02395% CI: [-9.4, -0.7]Mixed Models Analysis
Secondary

Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Reaction Times for Hits and Correct Rejections

Memory search task aims at measuring serial search processes to be carried out in working memory. There are 2 blocks (loads) with 40 trials each. Load 1 has 1 target to remember (one animal). A yes is required whenever the target is part of displayed set of 4 animals. Load 2 has 2 animals. A yes is required whenever one of the animals appears in successively displayed sets of 4 animals. Targets are present in 50% of the trials. Reaction time (RT) for hits is mean RT of correct yes responses to targets. RT correct rejections are mean RTs of correct no responses when target was missing.

Time frame: Baseline, 8 Weeks

Population: Number of participants with baseline and a non-missing postbaseline value at visit.

ArmMeasureGroupValue (MEAN)Dispersion
AtomoxetineAmsterdam Neuropsychological Tasks (ANT): Memory Search Task - Reaction Times for Hits and Correct RejectionsLoad 1 Baseline (n=33, n=35)1051.9 millisecondsStandard Deviation 338.41
AtomoxetineAmsterdam Neuropsychological Tasks (ANT): Memory Search Task - Reaction Times for Hits and Correct RejectionsLoad 1 8 Week (n=34, n=34)1014.8 millisecondsStandard Deviation 394.58
AtomoxetineAmsterdam Neuropsychological Tasks (ANT): Memory Search Task - Reaction Times for Hits and Correct RejectionsLoad 2 Baseline (n=32, n=34)1411.0 millisecondsStandard Deviation 357.5
AtomoxetineAmsterdam Neuropsychological Tasks (ANT): Memory Search Task - Reaction Times for Hits and Correct RejectionsLoad 2 8 Week (n=34, n=34)1130.4 millisecondsStandard Deviation 460.66
AtomoxetineAmsterdam Neuropsychological Tasks (ANT): Memory Search Task - Reaction Times for Hits and Correct RejectionsReaction Time Hits Load 1 Baseline (n=33, n=35)932.7 millisecondsStandard Deviation 295.14
AtomoxetineAmsterdam Neuropsychological Tasks (ANT): Memory Search Task - Reaction Times for Hits and Correct RejectionsReaction Time Hits Load 1 8 Week (n=34, n=34)882.4 millisecondsStandard Deviation 327.3
AtomoxetineAmsterdam Neuropsychological Tasks (ANT): Memory Search Task - Reaction Times for Hits and Correct RejectionsReaction Time Hits Load 2 Baseline (n=32, n=34)1131.5 millisecondsStandard Deviation 293.84
AtomoxetineAmsterdam Neuropsychological Tasks (ANT): Memory Search Task - Reaction Times for Hits and Correct RejectionsReaction Time Hits Load 2 8 Week (n=34, n=34)1060.0 millisecondsStandard Deviation 343.53
PlaceboAmsterdam Neuropsychological Tasks (ANT): Memory Search Task - Reaction Times for Hits and Correct RejectionsReaction Time Hits Load 2 8 Week (n=34, n=34)1110.8 millisecondsStandard Deviation 445.61
PlaceboAmsterdam Neuropsychological Tasks (ANT): Memory Search Task - Reaction Times for Hits and Correct RejectionsLoad 1 Baseline (n=33, n=35)1010.4 millisecondsStandard Deviation 382.92
PlaceboAmsterdam Neuropsychological Tasks (ANT): Memory Search Task - Reaction Times for Hits and Correct RejectionsReaction Time Hits Load 1 Baseline (n=33, n=35)881.7 millisecondsStandard Deviation 304.42
PlaceboAmsterdam Neuropsychological Tasks (ANT): Memory Search Task - Reaction Times for Hits and Correct RejectionsLoad 1 8 Week (n=34, n=34)928.7 millisecondsStandard Deviation 301.04
PlaceboAmsterdam Neuropsychological Tasks (ANT): Memory Search Task - Reaction Times for Hits and Correct RejectionsReaction Time Hits Load 2 Baseline (n=32, n=34)1111.8 millisecondsStandard Deviation 442.97
PlaceboAmsterdam Neuropsychological Tasks (ANT): Memory Search Task - Reaction Times for Hits and Correct RejectionsLoad 2 Baseline (n=32, n=34)1387.2 millisecondsStandard Deviation 595.37
PlaceboAmsterdam Neuropsychological Tasks (ANT): Memory Search Task - Reaction Times for Hits and Correct RejectionsReaction Time Hits Load 1 8 Week (n=34, n=34)786.8 millisecondsStandard Deviation 257.19
PlaceboAmsterdam Neuropsychological Tasks (ANT): Memory Search Task - Reaction Times for Hits and Correct RejectionsLoad 2 8 Week (n=34, n=34)1294.2 millisecondsStandard Deviation 552.25
p-value: 0.22895% CI: [-230.4, 56]Mixed Models Analysis
p-value: 0.2695% CI: [-65.6, 240.8]Mixed Models Analysis
p-value: 0.23995% CI: [-47.3, 188.2]Mixed Models Analysis
p-value: 0.12895% CI: [-35.9, 281.4]Mixed Models Analysis
Secondary

Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Standard Deviation (SD) of Reaction Times for Hits and Correct Rejections

Task is the same as described in Outcome Measure #14. Standard deviations of reaction times (RT) assess intraindividual variability in RT referring to the two conditions creating hits and correct rejections as mentioned in Outcome Measure #14.

Time frame: Baseline, 8 weeks

Population: Number of participants with baseline and a non-missing postbaseline value at visit.

ArmMeasureGroupValue (MEAN)Dispersion
AtomoxetineAmsterdam Neuropsychological Tasks (ANT): Memory Search Task - Standard Deviation (SD) of Reaction Times for Hits and Correct RejectionsLoad 1 Baseline (n=32, n=35)406.2 millisecondsStandard Deviation 280.59
AtomoxetineAmsterdam Neuropsychological Tasks (ANT): Memory Search Task - Standard Deviation (SD) of Reaction Times for Hits and Correct RejectionsLoad 1 8 Week (n=32, n=33)408.2 millisecondsStandard Deviation 342.39
AtomoxetineAmsterdam Neuropsychological Tasks (ANT): Memory Search Task - Standard Deviation (SD) of Reaction Times for Hits and Correct RejectionsLoad 2 Baseline (n=31, n=34)515.4 millisecondsStandard Deviation 275.4
AtomoxetineAmsterdam Neuropsychological Tasks (ANT): Memory Search Task - Standard Deviation (SD) of Reaction Times for Hits and Correct RejectionsLoad 2 8 Week (n=32, n=33)544.9 millisecondsStandard Deviation 338.26
AtomoxetineAmsterdam Neuropsychological Tasks (ANT): Memory Search Task - Standard Deviation (SD) of Reaction Times for Hits and Correct RejectionsSD Hits Load 1 Baseline (n=32, n=34)308.7 millisecondsStandard Deviation 239.1
AtomoxetineAmsterdam Neuropsychological Tasks (ANT): Memory Search Task - Standard Deviation (SD) of Reaction Times for Hits and Correct RejectionsSD Hits Load 1 8 Week (n=33, n=33)261.6 millisecondsStandard Deviation 231.32
AtomoxetineAmsterdam Neuropsychological Tasks (ANT): Memory Search Task - Standard Deviation (SD) of Reaction Times for Hits and Correct RejectionsSD Hits Load 2 Baseline (n=31, n=34)416.8 millisecondsStandard Deviation 226.87
AtomoxetineAmsterdam Neuropsychological Tasks (ANT): Memory Search Task - Standard Deviation (SD) of Reaction Times for Hits and Correct RejectionsSD Hits Load 2 8 Week (n=32, n=33)380.6 millisecondsStandard Deviation 280.36
PlaceboAmsterdam Neuropsychological Tasks (ANT): Memory Search Task - Standard Deviation (SD) of Reaction Times for Hits and Correct RejectionsSD Hits Load 2 8 Week (n=32, n=33)501.0 millisecondsStandard Deviation 382.32
PlaceboAmsterdam Neuropsychological Tasks (ANT): Memory Search Task - Standard Deviation (SD) of Reaction Times for Hits and Correct RejectionsLoad 1 Baseline (n=32, n=35)415.0 millisecondsStandard Deviation 324.66
PlaceboAmsterdam Neuropsychological Tasks (ANT): Memory Search Task - Standard Deviation (SD) of Reaction Times for Hits and Correct RejectionsSD Hits Load 1 Baseline (n=32, n=34)320.3 millisecondsStandard Deviation 263.73
PlaceboAmsterdam Neuropsychological Tasks (ANT): Memory Search Task - Standard Deviation (SD) of Reaction Times for Hits and Correct RejectionsLoad 1 8 Week (n=32, n=33)353.2 millisecondsStandard Deviation 273.16
PlaceboAmsterdam Neuropsychological Tasks (ANT): Memory Search Task - Standard Deviation (SD) of Reaction Times for Hits and Correct RejectionsSD Hits Load 2 Baseline (n=31, n=34)424.6 millisecondsStandard Deviation 301.2
PlaceboAmsterdam Neuropsychological Tasks (ANT): Memory Search Task - Standard Deviation (SD) of Reaction Times for Hits and Correct RejectionsLoad 2 Baseline (n=31, n=34)577.4 millisecondsStandard Deviation 340.89
PlaceboAmsterdam Neuropsychological Tasks (ANT): Memory Search Task - Standard Deviation (SD) of Reaction Times for Hits and Correct RejectionsSD Hits Load 1 8 Week (n=33, n=33)232.5 millisecondsStandard Deviation 165.44
PlaceboAmsterdam Neuropsychological Tasks (ANT): Memory Search Task - Standard Deviation (SD) of Reaction Times for Hits and Correct RejectionsLoad 2 8 Week (n=32, n=33)580.5 millisecondsStandard Deviation 375.88
p-value: 0.05195% CI: [-351.5, 0.5]Mixed Models Analysis
p-value: 0.01895% CI: [38, 398.2]Mixed Models Analysis
p-value: 0.10395% CI: [-35.7, 383]Mixed Models Analysis
p-value: 0.04295% CI: [7.5, 403.6]Mixed Models Analysis
Secondary

Amsterdam Neuropsychological Tasks (ANT): Pursuit Motor Control Task - Accuracy

A complex visuo-motor flexibility task that aims at measuring eye-hand co-ordination and fine motor control. By moving mouse cursor, the child is required to follow as closely as possible a target that randomly moves across the PC-screen. Accuracy is the mean distance between the mouse cursor and the moving target.

Time frame: Baseline, 8 weeks

Population: Number of participants with baseline and non-missing postbaseline value at visit.

ArmMeasureGroupValue (MEAN)Dispersion
AtomoxetineAmsterdam Neuropsychological Tasks (ANT): Pursuit Motor Control Task - AccuracyBaseline (n=30,n=33)7.8 millimetersStandard Deviation 5.62
AtomoxetineAmsterdam Neuropsychological Tasks (ANT): Pursuit Motor Control Task - Accuracy8 Week (n=31,n=33)8.2 millimetersStandard Deviation 6.88
PlaceboAmsterdam Neuropsychological Tasks (ANT): Pursuit Motor Control Task - AccuracyBaseline (n=30,n=33)8.1 millimetersStandard Deviation 5.49
PlaceboAmsterdam Neuropsychological Tasks (ANT): Pursuit Motor Control Task - Accuracy8 Week (n=31,n=33)10.1 millimetersStandard Deviation 11.92
p-value: 0.12895% CI: [-16.9, 2.3]Mixed Models Analysis
Secondary

Amsterdam Neuropsychological Tasks (ANT): Pursuit Motor Control Task - Stability of Movement

A complex visuo-motor flexibility task that measures eye-hand co-ordination and fine motor control. By moving mouse cursor, the child is required to follow as closely as possible a target that randomly moves across the PC-screen. Stability is within subject variability of mean distance between cursor and target.

Time frame: Baseline, 8 weeks

Population: Number of participants with baseline and non-missing postbaseline value at visit.

ArmMeasureGroupValue (MEAN)Dispersion
AtomoxetineAmsterdam Neuropsychological Tasks (ANT): Pursuit Motor Control Task - Stability of MovementBaseline (n=30,n=33)7.6 millimetersStandard Deviation 8.24
AtomoxetineAmsterdam Neuropsychological Tasks (ANT): Pursuit Motor Control Task - Stability of Movement8 Week (n=31,n=33)8.2 millimetersStandard Deviation 8.61
PlaceboAmsterdam Neuropsychological Tasks (ANT): Pursuit Motor Control Task - Stability of MovementBaseline (n=30,n=33)8.2 millimetersStandard Deviation 7.9
PlaceboAmsterdam Neuropsychological Tasks (ANT): Pursuit Motor Control Task - Stability of Movement8 Week (n=31,n=33)9.4 millimetersStandard Deviation 9.24
p-value: 0.02295% CI: [-11.2, -1]Mixed Models Analysis
Secondary

Children's Social Behavior Questionnaire (CSBQ) Total Score

CSBQ is filled out by parents and consists of 49 items. Items are rated in an ordinal rather than a discrete fashion in order to establish the extent to which problems are present. The CSBQ consists of six subscales. Individual item scores range from 0=does not apply to 2=applies clearly. Total score ranges from 0 to 98.

Time frame: Baseline, 8 weeks, 28 weeks

Population: Randomized participants with value at timepoint.

ArmMeasureGroupValue (MEAN)Dispersion
AtomoxetineChildren's Social Behavior Questionnaire (CSBQ) Total ScoreBaseline (n=48, n=49)53.6 units on a scaleStandard Deviation 14.81
AtomoxetineChildren's Social Behavior Questionnaire (CSBQ) Total Score8 Week (n=43, n=46)46.1 units on a scaleStandard Deviation 15.88
AtomoxetineChildren's Social Behavior Questionnaire (CSBQ) Total Score28 Week (n=38, n=35)40.4 units on a scaleStandard Deviation 19.55
PlaceboChildren's Social Behavior Questionnaire (CSBQ) Total ScoreBaseline (n=48, n=49)52.4 units on a scaleStandard Deviation 15.97
PlaceboChildren's Social Behavior Questionnaire (CSBQ) Total Score8 Week (n=43, n=46)50.2 units on a scaleStandard Deviation 14.62
PlaceboChildren's Social Behavior Questionnaire (CSBQ) Total Score28 Week (n=38, n=35)43.6 units on a scaleStandard Deviation 17.26
p-value: 0.06995% CI: [-8.1, 0.3]ANCOVA
Secondary

Clinical Global Impressions-ADHD-Improvement (CGI-ADHD - I)

Measures total improvement (or worsening) of a patient's ADHD symptoms from the beginning of treatment (1=very much improved, 7=very much worsened).

Time frame: 8 weeks, 28 weeks

Population: Number of randomized participants with values at timepoint.

ArmMeasureGroupValue (MEAN)Dispersion
AtomoxetineClinical Global Impressions-ADHD-Improvement (CGI-ADHD - I)8 Week Improvement Score3.5 units on a scaleStandard Deviation 1.08
AtomoxetineClinical Global Impressions-ADHD-Improvement (CGI-ADHD - I)28 Week Improvement Score (n=39, n=35)2.5 units on a scaleStandard Deviation 1.14
PlaceboClinical Global Impressions-ADHD-Improvement (CGI-ADHD - I)8 Week Improvement Score3.9 units on a scaleStandard Deviation 0.96
PlaceboClinical Global Impressions-ADHD-Improvement (CGI-ADHD - I)28 Week Improvement Score (n=39, n=35)2.7 units on a scaleStandard Deviation 1.05
p-value: 0.92195% CI: [-0.5, 0.4]Mixed Models Analysis
Secondary

Conners' Teacher Rating Scale - Revised: Short Form (CTRS-R:S)

A 28-item rating scale (0 \[not at all/never\] to 3 \[very much true/very often\]) completed by the teacher to assess problem behaviors related to ADHD. Subscale total scores range from 0 to 15 for Oppositional and Cognitive Problems, 0 to 21 for Hyperactivity, and 0 to 36 for ADHD Index.

Time frame: Baseline, 8 weeks, 28 weeks

Population: Number of randomized participants who had a value at timepoint.

ArmMeasureGroupValue (MEAN)Dispersion
AtomoxetineConners' Teacher Rating Scale - Revised: Short Form (CTRS-R:S)Oppositional: Baseline (n=42, n=44)4.1 units on a scaleStandard Deviation 3.54
AtomoxetineConners' Teacher Rating Scale - Revised: Short Form (CTRS-R:S)Oppositional: 8 Week (n=36, n=36)3.8 units on a scaleStandard Deviation 4.43
AtomoxetineConners' Teacher Rating Scale - Revised: Short Form (CTRS-R:S)Oppositional: 28 Week (n=26, n= 25)2.3 units on a scaleStandard Deviation 3.33
AtomoxetineConners' Teacher Rating Scale - Revised: Short Form (CTRS-R:S)Hyperactivity: Baseline (n=42, n=44)8.8 units on a scaleStandard Deviation 5.5
AtomoxetineConners' Teacher Rating Scale - Revised: Short Form (CTRS-R:S)Hyperactivity: 8 Week (n=36, n=36)7.6 units on a scaleStandard Deviation 5.54
AtomoxetineConners' Teacher Rating Scale - Revised: Short Form (CTRS-R:S)Hyperactivity: 28 Week (n=26, n=25)6.0 units on a scaleStandard Deviation 4.9
AtomoxetineConners' Teacher Rating Scale - Revised: Short Form (CTRS-R:S)Cognitive/Attention: Baseline (n=40, n=44)6.8 units on a scaleStandard Deviation 4.45
AtomoxetineConners' Teacher Rating Scale - Revised: Short Form (CTRS-R:S)Cognitive/Attention: 8 Week (n=34, n=36)6.1 units on a scaleStandard Deviation 4.56
AtomoxetineConners' Teacher Rating Scale - Revised: Short Form (CTRS-R:S)Cognitive/Attention: 28 Week (n=26, n=25)4.7 units on a scaleStandard Deviation 3.58
AtomoxetineConners' Teacher Rating Scale - Revised: Short Form (CTRS-R:S)ADHD: Baseline (n=42, n=44)18.5 units on a scaleStandard Deviation 9.27
AtomoxetineConners' Teacher Rating Scale - Revised: Short Form (CTRS-R:S)ADHD: 8 Week (n=36, n=36)15.8 units on a scaleStandard Deviation 9.85
AtomoxetineConners' Teacher Rating Scale - Revised: Short Form (CTRS-R:S)ADHD: 28 Week (n=26, n=25)13.5 units on a scaleStandard Deviation 8.61
PlaceboConners' Teacher Rating Scale - Revised: Short Form (CTRS-R:S)ADHD: 8 Week (n=36, n=36)17.2 units on a scaleStandard Deviation 8.69
PlaceboConners' Teacher Rating Scale - Revised: Short Form (CTRS-R:S)Oppositional: Baseline (n=42, n=44)3.6 units on a scaleStandard Deviation 3.53
PlaceboConners' Teacher Rating Scale - Revised: Short Form (CTRS-R:S)Cognitive/Attention: Baseline (n=40, n=44)4.8 units on a scaleStandard Deviation 3.68
PlaceboConners' Teacher Rating Scale - Revised: Short Form (CTRS-R:S)Oppositional: 8 Week (n=36, n=36)3.4 units on a scaleStandard Deviation 3.35
PlaceboConners' Teacher Rating Scale - Revised: Short Form (CTRS-R:S)ADHD: Baseline (n=42, n=44)18.1 units on a scaleStandard Deviation 7.49
PlaceboConners' Teacher Rating Scale - Revised: Short Form (CTRS-R:S)Oppositional: 28 Week (n=26, n= 25)1.4 units on a scaleStandard Deviation 1.98
PlaceboConners' Teacher Rating Scale - Revised: Short Form (CTRS-R:S)Cognitive/Attention: 8 Week (n=34, n=36)4.6 units on a scaleStandard Deviation 3.53
PlaceboConners' Teacher Rating Scale - Revised: Short Form (CTRS-R:S)Hyperactivity: Baseline (n=42, n=44)8.2 units on a scaleStandard Deviation 5.06
PlaceboConners' Teacher Rating Scale - Revised: Short Form (CTRS-R:S)ADHD: 28 Week (n=26, n=25)12.5 units on a scaleStandard Deviation 5.95
PlaceboConners' Teacher Rating Scale - Revised: Short Form (CTRS-R:S)Hyperactivity: 8 Week (n=36, n=36)8.3 units on a scaleStandard Deviation 5.63
PlaceboConners' Teacher Rating Scale - Revised: Short Form (CTRS-R:S)Cognitive/Attention: 28 Week (n=26, n=25)4.6 units on a scaleStandard Deviation 3.85
PlaceboConners' Teacher Rating Scale - Revised: Short Form (CTRS-R:S)Hyperactivity: 28 Week (n=26, n=25)5.2 units on a scaleStandard Deviation 4.13
p-value: 0.36995% CI: [-1.8, 0.7]ANCOVA
p-value: 0.02495% CI: [-3.7, -0.3]ANCOVA
p-value: 0.17995% CI: [-1.7, 0.3]ANCOVA
p-value: 0.07795% CI: [-5.6, 0.3]ANCOVA
Secondary

Cytochrome P450 2D6 Genotype

Genotype characterization was used to determine participants' metabolic status.

Time frame: baseline

Population: All randomized participants.

ArmMeasureGroupValue (NUMBER)
AtomoxetineCytochrome P450 2D6 GenotypeExtensive Metabolizer28 participants
AtomoxetineCytochrome P450 2D6 GenotypeIntermediate Metabolizer13 participants
AtomoxetineCytochrome P450 2D6 GenotypePoor Metabolizer6 participants
AtomoxetineCytochrome P450 2D6 GenotypeMissing1 participants
PlaceboCytochrome P450 2D6 GenotypeMissing0 participants
PlaceboCytochrome P450 2D6 GenotypeExtensive Metabolizer28 participants
PlaceboCytochrome P450 2D6 GenotypePoor Metabolizer6 participants
PlaceboCytochrome P450 2D6 GenotypeIntermediate Metabolizer15 participants
Secondary

General Health Questionnaire (GHQ) Total Score

Parental distress is measured with the GHQ. The raw total score (based on 0-0-1-1 scoring system) can be used as an overall index of psychological distress, ranging from 0 to 12 with higher scores indicating more distress.

Time frame: Baseline, 8 weeks, 28 weeks

Population: Randomized participants with value at timepoint.

ArmMeasureGroupValue (MEAN)Dispersion
AtomoxetineGeneral Health Questionnaire (GHQ) Total ScoreBaseline (n=48, n=49)2.9 units on a scaleStandard Deviation 3.45
AtomoxetineGeneral Health Questionnaire (GHQ) Total Score8 Week (n=43, n=46)2.3 units on a scaleStandard Deviation 3.35
AtomoxetineGeneral Health Questionnaire (GHQ) Total Score28 Week (n=38, n=36)1.7 units on a scaleStandard Deviation 2.61
PlaceboGeneral Health Questionnaire (GHQ) Total ScoreBaseline (n=48, n=49)4.0 units on a scaleStandard Deviation 3.79
PlaceboGeneral Health Questionnaire (GHQ) Total Score8 Week (n=43, n=46)3.1 units on a scaleStandard Deviation 3.31
PlaceboGeneral Health Questionnaire (GHQ) Total Score28 Week (n=38, n=36)2.3 units on a scaleStandard Deviation 2.7
p-value: 0.59895% CI: [-1.6, 0.9]ANCOVA
Secondary

Nijmeegse Ouderlijke Stress Index (NOSI) Total Score

The NOSI contains 123 items to be completed by the primary caregiver. Individual item scores range from 1 (completely agree) to 6 (completely disagree). Total scores range from 123 to 738.

Time frame: Baseline, 8 weeks, 28 weeks

Population: Randomized participants with value at timepoint.

ArmMeasureGroupValue (MEAN)Dispersion
AtomoxetineNijmeegse Ouderlijke Stress Index (NOSI) Total ScoreBaseline (n=42, n=44)368.6 units on a scaleStandard Deviation 79.22
AtomoxetineNijmeegse Ouderlijke Stress Index (NOSI) Total Score8 Week (n=38, n=39)350.0 units on a scaleStandard Deviation 75.07
AtomoxetineNijmeegse Ouderlijke Stress Index (NOSI) Total Score28 Week (n=35, n=34)325.2 units on a scaleStandard Deviation 85.76
PlaceboNijmeegse Ouderlijke Stress Index (NOSI) Total ScoreBaseline (n=42, n=44)379.5 units on a scaleStandard Deviation 78.74
PlaceboNijmeegse Ouderlijke Stress Index (NOSI) Total Score8 Week (n=38, n=39)368.8 units on a scaleStandard Deviation 81.83
PlaceboNijmeegse Ouderlijke Stress Index (NOSI) Total Score28 Week (n=35, n=34)328.4 units on a scaleStandard Deviation 89.23
p-value: 0.31895% CI: [-33.3, 11]ANCOVA
Secondary

Sleep Measure Scale

10-item parent-based scale assessing sleep problems (6 point Likert scale). Scores: Difficulty falling asleep (1-6); Quality of sleep (3-18); Functional outcome (6-36). Lower scores indicate higher problems with item. Open-ended items: Time to fall asleep (1 \[0-15 minutes\] to 5 \[\>1 hour\]); Total hours (numbers associated with hours of sleep).

Time frame: Baseline, 8 weeks, 28 weeks

Population: Randomized participants with a value at timepoint.

ArmMeasureGroupValue (MEAN)Dispersion
AtomoxetineSleep Measure ScaleDifficulty Falling Asleep: Baseline (n=48, n=49)3.4 units on a scaleStandard Deviation 1.91
AtomoxetineSleep Measure ScaleTotal Hours of Sleep: 28 Week (n=36, n=34)8.9 units on a scaleStandard Deviation 1.61
AtomoxetineSleep Measure ScaleTime to Fall Asleep: Baseline (n=48, n=49)2.9 units on a scaleStandard Deviation 1.49
AtomoxetineSleep Measure ScaleQuality of Sleep: Baseline (n=48, n=49)14.1 units on a scaleStandard Deviation 2.85
AtomoxetineSleep Measure ScaleDifficulty Falling Asleep: 8 Week (n=43, n=46)3.6 units on a scaleStandard Deviation 1.8
AtomoxetineSleep Measure ScaleQuality of Sleep: 8 Week (n=43, n=46)14.2 units on a scaleStandard Deviation 3.08
AtomoxetineSleep Measure ScaleTime to Fall Asleep: 28 Week (n=35, n=35)3.1 units on a scaleStandard Deviation 1.49
AtomoxetineSleep Measure ScaleQuality of Sleep: 28 Week (n=38, n=36)14.6 units on a scaleStandard Deviation 2.88
AtomoxetineSleep Measure ScaleDifficulty Falling Asleep: 28 Week (n=38, n=36)3.2 units on a scaleStandard Deviation 1.76
AtomoxetineSleep Measure ScaleFunctional Outcome During Day:Baseline (n=48,n=49)29.6 units on a scaleStandard Deviation 4.69
AtomoxetineSleep Measure ScaleTime to Fall Asleep: 8 Week (n=43, n=46)2.6 units on a scaleStandard Deviation 1.43
AtomoxetineSleep Measure ScaleFunctional Outcome During Day:8 Week (n=43,n=46)29.1 units on a scaleStandard Deviation 5.09
AtomoxetineSleep Measure ScaleTotal Hours of Sleep: Baseline (n=48, n=49)9.1 units on a scaleStandard Deviation 1.38
AtomoxetineSleep Measure ScaleFunctional Outcome During Day:28Week (n=38,n=36)27.8 units on a scaleStandard Deviation 6.38
AtomoxetineSleep Measure ScaleTotal Hours of Sleep: 8 Weeks (n=42, n=46)8.9 units on a scaleStandard Deviation 1.49
PlaceboSleep Measure ScaleFunctional Outcome During Day:28Week (n=38,n=36)29.6 units on a scaleStandard Deviation 4.76
PlaceboSleep Measure ScaleTotal Hours of Sleep: 8 Weeks (n=42, n=46)9.1 units on a scaleStandard Deviation 1.51
PlaceboSleep Measure ScaleTime to Fall Asleep: Baseline (n=48, n=49)2.8 units on a scaleStandard Deviation 1.41
PlaceboSleep Measure ScaleTime to Fall Asleep: 8 Week (n=43, n=46)3.0 units on a scaleStandard Deviation 1.34
PlaceboSleep Measure ScaleTime to Fall Asleep: 28 Week (n=35, n=35)2.6 units on a scaleStandard Deviation 1.14
PlaceboSleep Measure ScaleDifficulty Falling Asleep: Baseline (n=48, n=49)3.3 units on a scaleStandard Deviation 1.58
PlaceboSleep Measure ScaleDifficulty Falling Asleep: 8 Week (n=43, n=46)3.3 units on a scaleStandard Deviation 1.64
PlaceboSleep Measure ScaleDifficulty Falling Asleep: 28 Week (n=38, n=36)3.7 units on a scaleStandard Deviation 1.69
PlaceboSleep Measure ScaleTotal Hours of Sleep: Baseline (n=48, n=49)9.3 units on a scaleStandard Deviation 1.46
PlaceboSleep Measure ScaleTotal Hours of Sleep: 28 Week (n=36, n=34)9.2 units on a scaleStandard Deviation 1.12
PlaceboSleep Measure ScaleQuality of Sleep: Baseline (n=48, n=49)14.4 units on a scaleStandard Deviation 2.84
PlaceboSleep Measure ScaleQuality of Sleep: 8 Week (n=43, n=46)14.9 units on a scaleStandard Deviation 2.86
PlaceboSleep Measure ScaleQuality of Sleep: 28 Week (n=38, n=36)15.0 units on a scaleStandard Deviation 2.35
PlaceboSleep Measure ScaleFunctional Outcome During Day:Baseline (n=48,n=49)30.0 units on a scaleStandard Deviation 4.07
PlaceboSleep Measure ScaleFunctional Outcome During Day:8 Week (n=43,n=46)30.0 units on a scaleStandard Deviation 4.8
p-value: 0.02895% CI: [-1, -0.1]ANCOVA
p-value: 0.40795% CI: [-0.3, 0.9]ANCOVA
p-value: 0.65295% CI: [-0.6, 0.4]ANCOVA
p-value: 0.11295% CI: [-1.7, 0.2]ANCOVA
p-value: 0.18895% CI: [-2.9, 0.6]ANCOVA

Source: ClinicalTrials.gov · Data processed: Mar 26, 2026